International Biotechnology Trust’s KalVista Pharmaceuticals KALV Stock Holding History

International Biotechnology Trust’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-316,133	Closed	-$4.59M	–	66
2022 Q3	$4.59M	Buy	316,133 +312,373	+8,308%	+$4.37M	1.47%	22
2022 Q2	$383K	Sell	3,760 -379,473	-99%	-$4.19M	4%	6
2022 Q1	$10.8M	Hold	383,233	–	–	2.44%	15
2021 Q4	$5.07M	Hold	383,233	–	–	1.13%	29
2021 Q3	$6.69M	Buy	383,233 +100,000	+35%	+$2.03M	1.61%	21
2021 Q2	$6.79M	Buy	283,233 +68,700	+32%	+$1.8M	1.79%	19
2021 Q1	$5.49M	Buy	214,533 +37,100	+21%	+$975K	1.45%	21
2020 Q4	$3.37M	Hold	177,433	–	–	0.92%	23
2020 Q3	$2.23M	Hold	177,433	–	–	0.72%	27
2020 Q2	$2.25M	Sell	177,433 -50,000	-22%	-$532K	0.75%	26
2020 Q1	$1.73M	Sell	227,433 -50,000	-18%	-$675K	0.79%	24
2019 Q4	$4.92M	Buy	277,433 +100,000	+56%	+$1.31M	1.77%	21
2019 Q3	$2.06M	Sell	177,433 -10,166	-5%	-$164K	0.95%	25
2019 Q2	$4.17M	Sell	187,599 -25,462	-12%	-$597K	1.54%	21
2019 Q1	$6.06M	Sell	213,061 -106,383	-33%	-$2.31M	2.24%	15
2018 Q4	$4.95M	Sell	319,444 -2,992	-0.9%	-$60.1K	3.07%	12
2018 Q3	$5.47M	Hold	322,436	–	–	2.6%	15
2018 Q2	$2.61M	Hold	322,436	–	–	1%	35
2018 Q1	$3.01M	Hold	322,436	–	–	1.17%	23
2017 Q4	$3.14M	Hold	322,436	–	–	1.11%	27
2017 Q3	$2.15M	Hold	322,436	–	–	0.84%	33
2017 Q2	$2.28M	Hold	322,436	–	–	0.86%	36
2017 Q1	$2.52M	Hold	322,436	–	–	0.96%	28
2016 Q4	$2.19M	Buy	+322,436	New	+$2.38M	0.98%	22

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

International Biotechnology Trust's KALV Position: Q4 2022 in Review

International Biotechnology Trust sold out of KalVista Pharmaceuticals (KALV) in Q4 2022, closing a stake of 316,133 shares — an estimated $4.59M sold.

International Biotechnology Trust first reported a position in KALV in Q4 2016 and held it in 24 quarters. The position peaked at $10.8M in Q1 2022. 91 funds tracked by Wall St. Rank hold KALV as of Q4 2022.

International Biotechnology Trust reported no remaining KalVista Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
International Biotechnology Trust sold 316,133 KalVista Pharmaceuticals shares in Q4 2022, an estimated $4.59M.
International Biotechnology Trust first reported a position in KalVista Pharmaceuticals in Q4 2016 and held it in 24 quarters.
International Biotechnology Trust's KalVista Pharmaceuticals position peaked at $10.8M in Q1 2022.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2022.

Based on International Biotechnology Trust's 13F filing for Q4 2022, filed 1 Feb 2023.